Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02886728




Registration number
NCT02886728
Ethics application status
Date submitted
29/08/2016
Date registered
1/09/2016
Date last updated
1/06/2021

Titles & IDs
Public title
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Scientific title
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy
Secondary ID [1] 0 0
2016-000570-37
Secondary ID [2] 0 0
GS-US-417-0303
Universal Trial Number (UTN)
Trial acronym
FINCH 3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Filgotinib
Treatment: Drugs - Placebo to match filgotinib
Treatment: Drugs - MTX
Treatment: Drugs - Placebo to match MTX

Experimental: Filgotinib 200 mg + MTX - Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg

Experimental: Filgotinib 100 mg + MTX - Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg

Experimental: Filgotinib 200 mg Monotherapy - Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX

Active comparator: MTX Monotherapy - Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg


Treatment: Drugs: Filgotinib
Tablet(s) administered orally once daily

Treatment: Drugs: Placebo to match filgotinib
Tablet(s) administered orally once daily

Treatment: Drugs: MTX
Capsule(s) administered orally once weekly

Treatment: Drugs: Placebo to match MTX
Capsule(s) administered orally once weekly
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [1] 0 0
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
Timepoint [1] 0 0
Baseline; Week 24
Secondary outcome [2] 0 0
Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 24
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 24
Timepoint [3] 0 0
Baseline; Week 24
Secondary outcome [4] 0 0
Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
Timepoint [4] 0 0
Baseline; Week 24
Secondary outcome [5] 0 0
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 24
Timepoint [5] 0 0
Baseline; Week 24
Secondary outcome [6] 0 0
Change From Baseline in the mTSS at Week 52
Timepoint [6] 0 0
Baseline; Week 52
Secondary outcome [7] 0 0
Percentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, 12, 36, and 52
Timepoint [7] 0 0
Weeks 2, 4, 12, 36, and 52
Secondary outcome [8] 0 0
Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [8] 0 0
Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [9] 0 0
Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [9] 0 0
Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [10] 0 0
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 2, 4, 12, 36, and 52
Timepoint [10] 0 0
Baseline; Weeks 2, 4, 12, 36, and 52
Secondary outcome [11] 0 0
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [11] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [12] 0 0
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [12] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [13] 0 0
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [13] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [14] 0 0
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [14] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [15] 0 0
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [15] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [16] 0 0
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [16] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [17] 0 0
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score = 0.22 at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [17] 0 0
Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [18] 0 0
Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [18] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [19] 0 0
Percentage of Participants Who Achieved DAS28 (CRP) = 3.2 at Weeks 4, 12, 24, and 52
Timepoint [19] 0 0
Weeks 4, 12, 24, and 52
Secondary outcome [20] 0 0
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 2, 4, 12, 36, and 52
Timepoint [20] 0 0
Weeks 2, 4, 12, 36, and 52
Secondary outcome [21] 0 0
ACR N Percent Improvement (ACR-N) Response at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [21] 0 0
Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [22] 0 0
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [22] 0 0
Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [23] 0 0
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [23] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [24] 0 0
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 12, 24, 36, and 52
Timepoint [24] 0 0
Baseline; Weeks 2, 4, 12, 24, 36, and 52
Secondary outcome [25] 0 0
Percentage of Participants With no Radiographic Progression From Baseline at Weeks 24, and 52
Timepoint [25] 0 0
Baseline; Weeks 24, and 52
Secondary outcome [26] 0 0
SF-36 PCS Score at Weeks 4, 12, 24, 36, and 52
Timepoint [26] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [27] 0 0
Change From Baseline in SF-36 PCS Score at Weeks 4, 12, 36, and 52
Timepoint [27] 0 0
Baseline; Weeks 4, 12, 36, and 52
Secondary outcome [28] 0 0
SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, 24, 36, and 52
Timepoint [28] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [29] 0 0
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, 24, 36, and 52
Timepoint [29] 0 0
Baseline; Weeks 4, 12, 24, 36, and 52
Secondary outcome [30] 0 0
FACIT-Fatigue Score at Weeks 4, 12, 24, 36, and 52
Timepoint [30] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [31] 0 0
Change From Baseline in FACIT-Fatigue Score at Weeks 4, 12, 36, and 52
Timepoint [31] 0 0
Baseline; Weeks 4, 12, 36, and 52
Secondary outcome [32] 0 0
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, 24, 36, and 52
Timepoint [32] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [33] 0 0
EQ-5D Current Health VAS at Weeks 4, 12, 24, 36, and 52
Timepoint [33] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [34] 0 0
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, 24, 36, and 52
Timepoint [34] 0 0
Baseline; Weeks 4, 12, 24, 36, and 52
Secondary outcome [35] 0 0
Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, 24, 36, and 52
Timepoint [35] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [36] 0 0
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, 24, 36, and 52
Timepoint [36] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [37] 0 0
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, 24, 36, and 52
Timepoint [37] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [38] 0 0
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, 24, 36, and 52
Timepoint [38] 0 0
Weeks 4, 12, 24, 36, and 52
Secondary outcome [39] 0 0
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, 24, 36, and 52
Timepoint [39] 0 0
Baseline; Weeks 4, 12, 24, 36, and 52
Secondary outcome [40] 0 0
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, 24, 36, and 52
Timepoint [40] 0 0
Baseline; Weeks 4, 12, 24, 36, and 52
Secondary outcome [41] 0 0
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, 24, 36, and 52
Timepoint [41] 0 0
Baseline; Weeks 4, 12, 24, 36, and 52
Secondary outcome [42] 0 0
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, 24, 36, and 52
Timepoint [42] 0 0
Baseline; Weeks 4, 12, 24, 36, and 52

Eligibility
Key inclusion criteria
Key

* Have a diagnosis of RA (2010 American College of Rheumatology [ACR]/European League Against Rheumatism [EULAR] criteria) and are ACR functional class I-III.
* Have = 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and = 6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both screening and Day 1.
* Limited or no prior treatment with MTX

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previous treatment with any janus kinase (JAK) inhibitor
* Previous therapy for longer than 3 months with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) other than MTX or hydroxychloroquine
* Use of any licensed or investigational biologic disease-modifying antirheumatic drugs (DMARDs)

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/08/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
8/05/2019
Sample size
Target
Accrual to date
Final
1252
Recruitment in Australia
Recruitment state(s)
QLD,TAS,WA
Recruitment hospital [1] 0 0
- Maroochydore
Recruitment hospital [2] 0 0
- Hobart
Recruitment hospital [3] 0 0
- Victoria Park
Recruitment postcode(s) [1] 0 0
- Maroochydore
Recruitment postcode(s) [2] 0 0
- Hobart
Recruitment postcode(s) [3] 0 0
- Victoria Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New Hampshire
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Caba
Country [26] 0 0
Argentina
State/province [26] 0 0
Mendoza
Country [27] 0 0
Argentina
State/province [27] 0 0
Quilmes
Country [28] 0 0
Argentina
State/province [28] 0 0
San Fernando
Country [29] 0 0
Argentina
State/province [29] 0 0
San Juan
Country [30] 0 0
Argentina
State/province [30] 0 0
San Miguel de Tucumán
Country [31] 0 0
Belgium
State/province [31] 0 0
Flemish Brabant
Country [32] 0 0
Belgium
State/province [32] 0 0
Genk
Country [33] 0 0
Belgium
State/province [33] 0 0
Hasselt
Country [34] 0 0
Belgium
State/province [34] 0 0
Merksem
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Dobrich
Country [36] 0 0
Bulgaria
State/province [36] 0 0
Haskovo
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Plovdiv
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Sofia
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Varna
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Vidin
Country [41] 0 0
Canada
State/province [41] 0 0
Ontario
Country [42] 0 0
Canada
State/province [42] 0 0
Quebec
Country [43] 0 0
Chile
State/province [43] 0 0
Santiago
Country [44] 0 0
Chile
State/province [44] 0 0
Temuco
Country [45] 0 0
Czechia
State/province [45] 0 0
Ostrava
Country [46] 0 0
Czechia
State/province [46] 0 0
Prague 2
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 4
Country [48] 0 0
Czechia
State/province [48] 0 0
Uherske Hradiste
Country [49] 0 0
Germany
State/province [49] 0 0
Aachen
Country [50] 0 0
Germany
State/province [50] 0 0
Hamburg
Country [51] 0 0
Germany
State/province [51] 0 0
Ratingen
Country [52] 0 0
Hong Kong
State/province [52] 0 0
Hong Kong
Country [53] 0 0
Hong Kong
State/province [53] 0 0
Tuen Mun
Country [54] 0 0
Hungary
State/province [54] 0 0
Bacs-Kiskun
Country [55] 0 0
Hungary
State/province [55] 0 0
Fejer
Country [56] 0 0
Hungary
State/province [56] 0 0
Budapest
Country [57] 0 0
Hungary
State/province [57] 0 0
Kistarcsa
Country [58] 0 0
India
State/province [58] 0 0
Ahmedabad
Country [59] 0 0
India
State/province [59] 0 0
Bangalore
Country [60] 0 0
India
State/province [60] 0 0
Delhi
Country [61] 0 0
India
State/province [61] 0 0
Jaipur
Country [62] 0 0
India
State/province [62] 0 0
Kolkata
Country [63] 0 0
India
State/province [63] 0 0
Lucknow
Country [64] 0 0
India
State/province [64] 0 0
Mangalore
Country [65] 0 0
India
State/province [65] 0 0
Mysuru
Country [66] 0 0
India
State/province [66] 0 0
Nagpur
Country [67] 0 0
India
State/province [67] 0 0
New Delhi
Country [68] 0 0
India
State/province [68] 0 0
Pune
Country [69] 0 0
India
State/province [69] 0 0
Secunderabad
Country [70] 0 0
India
State/province [70] 0 0
Srikakulam
Country [71] 0 0
India
State/province [71] 0 0
Surat
Country [72] 0 0
India
State/province [72] 0 0
Vadodara
Country [73] 0 0
India
State/province [73] 0 0
Visakhapatnam
Country [74] 0 0
Ireland
State/province [74] 0 0
Dublin 4
Country [75] 0 0
Israel
State/province [75] 0 0
Peta? Tiqwa
Country [76] 0 0
Italy
State/province [76] 0 0
Bologna
Country [77] 0 0
Italy
State/province [77] 0 0
Reggio Emilia
Country [78] 0 0
Japan
State/province [78] 0 0
Fukuoka
Country [79] 0 0
Japan
State/province [79] 0 0
Hamamatsu
Country [80] 0 0
Japan
State/province [80] 0 0
Hiroshima
Country [81] 0 0
Japan
State/province [81] 0 0
Kagoshima
Country [82] 0 0
Japan
State/province [82] 0 0
Kato
Country [83] 0 0
Japan
State/province [83] 0 0
Kawagoe
Country [84] 0 0
Japan
State/province [84] 0 0
Miyagi
Country [85] 0 0
Japan
State/province [85] 0 0
Nagaoka
Country [86] 0 0
Japan
State/province [86] 0 0
Nagasaki
Country [87] 0 0
Japan
State/province [87] 0 0
Okayama
Country [88] 0 0
Japan
State/province [88] 0 0
Sanuki
Country [89] 0 0
Japan
State/province [89] 0 0
Sapporo
Country [90] 0 0
Japan
State/province [90] 0 0
Sasebo
Country [91] 0 0
Japan
State/province [91] 0 0
Sayama
Country [92] 0 0
Japan
State/province [92] 0 0
Tokyo
Country [93] 0 0
Japan
State/province [93] 0 0
Ome
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Anyang-si
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Daegu
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Daejeon
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Incheon
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Seoul
Country [99] 0 0
Malaysia
State/province [99] 0 0
Batu Caves
Country [100] 0 0
Malaysia
State/province [100] 0 0
Kuala Lumpur
Country [101] 0 0
Mexico
State/province [101] 0 0
Yucatan
Country [102] 0 0
Mexico
State/province [102] 0 0
Chihuahua
Country [103] 0 0
Mexico
State/province [103] 0 0
Distrito Federal
Country [104] 0 0
Mexico
State/province [104] 0 0
Monterrey
Country [105] 0 0
Mexico
State/province [105] 0 0
Morelia
Country [106] 0 0
Mexico
State/province [106] 0 0
Mérida
Country [107] 0 0
New Zealand
State/province [107] 0 0
Canterbury
Country [108] 0 0
New Zealand
State/province [108] 0 0
Hamilton
Country [109] 0 0
New Zealand
State/province [109] 0 0
Newtown
Country [110] 0 0
New Zealand
State/province [110] 0 0
Papatoetoe
Country [111] 0 0
Poland
State/province [111] 0 0
Bialystok
Country [112] 0 0
Poland
State/province [112] 0 0
Bydgoszcz
Country [113] 0 0
Poland
State/province [113] 0 0
Bytom
Country [114] 0 0
Poland
State/province [114] 0 0
Dabrówka
Country [115] 0 0
Poland
State/province [115] 0 0
Elblag
Country [116] 0 0
Poland
State/province [116] 0 0
Gdynia
Country [117] 0 0
Poland
State/province [117] 0 0
Katowice
Country [118] 0 0
Poland
State/province [118] 0 0
Krakow
Country [119] 0 0
Poland
State/province [119] 0 0
Nowa Sól
Country [120] 0 0
Poland
State/province [120] 0 0
Poznan
Country [121] 0 0
Poland
State/province [121] 0 0
Torun
Country [122] 0 0
Poland
State/province [122] 0 0
Warszawa
Country [123] 0 0
Romania
State/province [123] 0 0
Mures
Country [124] 0 0
Romania
State/province [124] 0 0
Bucharest
Country [125] 0 0
Romania
State/province [125] 0 0
Oradea
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Barnaul
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Kemerovo
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Moscow
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Nizhniy Novgorod
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Saratov
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Yaroslavl
Country [132] 0 0
Serbia
State/province [132] 0 0
Belgrade
Country [133] 0 0
Slovakia
State/province [133] 0 0
Bratislava
Country [134] 0 0
Slovakia
State/province [134] 0 0
Prievidza
Country [135] 0 0
Slovakia
State/province [135] 0 0
Topol'cany
Country [136] 0 0
South Africa
State/province [136] 0 0
Cape Town
Country [137] 0 0
South Africa
State/province [137] 0 0
Durban
Country [138] 0 0
Spain
State/province [138] 0 0
Barcelona
Country [139] 0 0
Spain
State/province [139] 0 0
Barakaldo
Country [140] 0 0
Spain
State/province [140] 0 0
La Coruña
Country [141] 0 0
Spain
State/province [141] 0 0
Málaga
Country [142] 0 0
Spain
State/province [142] 0 0
Sabadell
Country [143] 0 0
Spain
State/province [143] 0 0
Santiago de Compostela
Country [144] 0 0
Spain
State/province [144] 0 0
Valencia
Country [145] 0 0
Taiwan
State/province [145] 0 0
Kaohsiung
Country [146] 0 0
Taiwan
State/province [146] 0 0
Taichung
Country [147] 0 0
Taiwan
State/province [147] 0 0
Tainan
Country [148] 0 0
Taiwan
State/province [148] 0 0
Taipei
Country [149] 0 0
Taiwan
State/province [149] 0 0
Taoyuan
Country [150] 0 0
Thailand
State/province [150] 0 0
Bangkok
Country [151] 0 0
Thailand
State/province [151] 0 0
Chiang Mai
Country [152] 0 0
Thailand
State/province [152] 0 0
Songkhla
Country [153] 0 0
Ukraine
State/province [153] 0 0
Dnipro
Country [154] 0 0
Ukraine
State/province [154] 0 0
Kharkiv
Country [155] 0 0
Ukraine
State/province [155] 0 0
Kherson
Country [156] 0 0
Ukraine
State/province [156] 0 0
Kyiv
Country [157] 0 0
Ukraine
State/province [157] 0 0
L'viv
Country [158] 0 0
Ukraine
State/province [158] 0 0
Vinnitsa
Country [159] 0 0
Ukraine
State/province [159] 0 0
Vinnytsya
Country [160] 0 0
Ukraine
State/province [160] 0 0
Zaporizhzhya
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Edinburgh
Country [162] 0 0
United Kingdom
State/province [162] 0 0
Newcastle upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Galapagos NV
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).
Trial website
https://clinicaltrials.gov/study/NCT02886728
Trial related presentations / publications
Westhovens R, Rigby W, van der Heijde D, Ching D, Bartok B, Matzkies F, et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis naive to methotrexate therapy: FINCH 3 primary outcome results. Ann Rheum Dis 2019; 78 (supplement 2): A259.
Tanaka Y, Atsumi T, Aletaha D, Bartok B, Pechonkina A, Han L, Emoto K, Kano S, Rajendran V, Takeuchi T. Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials. Rheumatol Ther. 2023 Feb;10(1):161-185. doi: 10.1007/s40744-022-00503-3. Epub 2022 Nov 3.
Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7.
Bingham CO 3rd, Walker D, Nash P, Lee SJ, Ye L, Hu H, Khalid JM, Combe B. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Arthritis Res Ther. 2022 Jan 3;24(1):11. doi: 10.1186/s13075-021-02677-7.
Aletaha D, Westhovens R, Gaujoux-Viala C, Adami G, Matsumoto A, Bird P, Messina OD, Buch MH, Bartok B, Yin Z, Guo Y, Hendrikx T, Burmester GR. Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. RMD Open. 2021 Aug;7(2):e001621. doi: 10.1136/rmdopen-2021-001621.
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewe RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 Jun;80(6):727-738. doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15.
Public notes

Contacts
Principal investigator
Name 0 0
Gilead Study Director
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02886728